AYTU
Aytu BioPharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
EXXUA is showing early commercial traction, management is emphasizing a large MDD market, and the company has reduced non-cash warrant volatility while keeping the legacy business profitable enough to fund launch investment. If script growth compounds and ex-U.S.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
EXXUA launch momentum may not sustain after the initial quarter, and reimbursement or pharmacy ordering noise could slow the revenue ramp.
Momentum
100
Value
57
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.30 · Bull $4.80 · Bear $0.95
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.33
Why
Momentum100 · Δ7d -
Value57 · Δ7d +0.2
Sentiment63 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.4
Sentiment
63
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 99.5 / Value 56.7 / Sentiment 63.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$23.08M
Beta
0.37
Shares Out
10.19M
P/E (TTM)
15.7
P/S (TTM)
0.46
P/FCF (TTM) · Derived
-5.46
Rev YoY
-16.2%
EPS YoY
-16.0%
Gross Margin
+67.6%
Op Margin
-13.2%
Net Debt
-$9.14M
Current Ratio
1.23
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology